Holen Sie sich die Stockscreener-App
1.815
1.83%
0.035
Schlusskurs vom Vortag:
$1.78
Offen:
$1.79
24-Stunden-Volumen:
84,318
Relative Volume:
0.21
Marktkapitalisierung:
$178.78M
Einnahmen:
$25.14M
Nettoeinkommen (Verlust:
$-21.57M
KGV:
-6.7222
EPS:
-0.27
Netto-Cashflow:
$-12.23M
1W Leistung:
-3.07%
1M Leistung:
-19.80%
6M Leistung:
-16.47%
1J Leistung:
-26.02%
1-Tages-Spanne:
$1.79
$1.86
1-Wochen-Bereich:
$1.725
$1.87
52-Wochen-Spanne:
$1.66
$3.29
Stereotaxis Inc Stock (STXS) Company Profile
Firmenname
Stereotaxis Inc
Sektor
Telefon
314-678-6100
Adresse
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Vergleichen Sie STXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
1.815 | 178.78M | 25.14M | -21.57M | -12.23M | -0.27 |
|
ISRG
Intuitive Surgical Inc
|
490.00 | 173.48B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
225.14 | 64.38B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
88.20 | 43.42B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
223.31 | 32.44B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.95 | 17.68B | 17.28B | 108.00M | 391.00M | 0.20 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2022-07-12 | Eingeleitet | Aegis Capital | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2022-01-05 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | Loop Capital | Buy |
| 2021-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-08 | Eingeleitet | Northland Capital | Outperform |
| 2020-04-09 | Eingeleitet | Cowen | Outperform |
| 2020-04-07 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Stereotaxis Inc Aktie (STXS) Neueste Nachrichten
Stereotaxis director Isaac Paul acquires $68,780 in common stock By Investing.com - Investing.com South Africa
Director Makes Bold Move with Major Stereotaxis Stock Purchase - TipRanks
Stereotaxis director Isaac Paul acquires $68,780 in common stock - Investing.com
Stereotaxis director Paul Isaac acquires $44,836 in common stock By Investing.com - Investing.com Canada
Stereotaxis director Paul Isaac acquires $44,836 in common stock - Investing.com Australia
Stereotaxis to Present at 37th Annual Roth Conference - GlobeNewswire
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission - Yahoo Finance
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn (NYSE:STXS) - Seeking Alpha
Q1 Earnings Estimate for Stereotaxis Issued By Roth Capital - Defense World
Stereotaxis, Inc. (AMEX:STXS) Q4 2024 Earnings Call Transcript - MSN
Stereotaxis submits catheter pair for FDA clearance - Robot Report
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval - MSN
Stereotaxis sees double digit revenue growth for FY25 - Yahoo Finance
Stereotaxis submits EMAGIN catheter for regulatory clearance - Yahoo Finance
Stereotaxis announces FDA regulatory submission for MAGiC Sweep catheter - Yahoo Finance
Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Stereotaxis Earnings Call: Growth Amid Challenges - TipRanks
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Stereotaxis earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Stereotaxis Q4 2024 misses forecasts, stock dips By Investing.com - Investing.com Canada
Stereotaxis seeks FDA nod for robotic catheter system By Investing.com - Investing.com Canada
Stereotaxis seeks FDA nod for robotic catheter - Investing.com India
Stereotaxis seeks FDA nod for robotic catheter system - Investing.com India
Stereotaxis seeks FDA nod for robotic catheter By Investing.com - Investing.com South Africa
Stereotaxis Inc Reports Q4 2024 Earnings: EPS of -$0.09 Misses E - GuruFocus.com
Stereotaxis Reports 2024 Full Year Financial Results - The Manila Times
Stereotaxis Submits FDA Application for EMAGIN™ 5F, First Robotically Navigated Catheter for Endovascular Procedures - Nasdaq
Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance - GlobeNewswire
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery - GlobeNewswire
Can Stereotaxis Revolutionize Stroke and Cancer Treatment? New Robotic Catheter Heads to FDA - StockTitan
Could This First-Ever Robotic Mapping Catheter Transform Cardiac Procedures? - StockTitan
Can Stereotaxis Turn Q4 Momentum Into Sustained Growth After Flat 2024 Results? - StockTitan
Stereotaxis Reports Strong Revenue Growth and Strategic Milestones - TipRanks
Stereotaxis, Inc. to Host Earnings Call - ACCESS Newswire
Stereotaxis (STXS) to Release Quarterly Earnings on Monday - Defense World
Stereotaxis Inc (STXS) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Stereotaxis Inc (STXS) Q4 2024: Everything You Need To Know Ahea - GuruFocus.com
Stereotaxis (STXS) Projected to Post Quarterly Earnings on Monday - MarketBeat
Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference - GlobeNewswire
Global Magnetic Ablation Catheters Market Poised for Significant Growth, Projected to Reach USD 1,114.4 Million by 2035 Driven by Technological Advancements and Rising Cardiovascular Cases | Future Market Insights, Inc. - GlobeNewswire Inc.
Legato Capital Management LLC Sells 111,859 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) - MarketBeat
Stock Market Sleeps On Stereotaxis MAGiC CE Mark (NYSE:STXS) - Seeking Alpha
SG Americas Securities LLC Has $60,000 Holdings in Stereotaxis, Inc. (NYSEAMERICAN:STXS) - Defense World
STXS Stock Gains Following the First Order for its GenesisX - MSN
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewswire
Finanzdaten der Stereotaxis Inc-Aktie (STXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):